The CREDENCE trial
The CREDENCE trial was the first to directly test the cardiovascular and renal benefits of a SGLT2 inhibitor (canagliflozin) in people with type 2 diabetes and albuminuric chronic kidney disease.
In the primary analysis, canagliflozin significantly reduced the risk for renal progression and death from renal or cardiovascular causes, and a more recent analysis showed this applied regardless of whether patients had pre-existing cardiovascular disease.
The CREDENCE investigators do not anticipate having new data ready in time for the 55th EASD Annual Meeting (EASD 2019), but will provide an overview of the findings to date:
Tuesday, September 17, 12:00–13:00, Joslin Hall, Fira Barcelona Gran Via, Spain
Session Chair: V. Perkovic, Australia
- Introduction and design. C. Pollock, Australia
- Renal outcomes. H. J. Lambers Heerspink, Netherlands
- Cardiovascular and safety outcomes. K. W. Mahaffey, USA
- Commentary. M. A. Nauck, Germany
What our Editorial Board said:
John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).